Search results
Exelixis' Growth Trajectory Depends on Leading Innovations in Cancer Treatments
GuruFocus.com via Yahoo Finance· 2 months agoExelixis Inc. (NASDAQ:EXEL) is a pharmaceutical company headquartered in Alameda, California that...
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
Zacks via Yahoo Finance· 5 months agoIt was a busy week for the biotech sector, with numerous study readouts and other updates. Quite a...
Will Keytruda & Gardasil Aid Merck (MRK) Sales in Q4 Earnings?
Zacks via Yahoo Finance· 1 year agoMerck MRK boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor, Keytruda,...
7 Myths About Kidney Cancer, Debunked
Time via Yahoo News· 1 year agodoctor holding orange ribbon. campaign to prevent skin cancer, melanoma, December orange Credit - Leonidas Santana—Getty Images Kidney cancer may well be...
Is Kidney Cancer Curable? Understanding the Odds
Verywell Health via Yahoo News· 4 months agoThere are several types of kidney (renal) cancer. Each type is potentially curable if it's found and treated early, before the cancer has a chance to...
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
Benzinga via Yahoo Finance· 1 year agoExelixis Inc (NASDAQ: EXEL) announced that the phase 3 CONTACT-03 study did not meet its primary...
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2
Zacks via Yahoo Finance· 9 months agoIovance Biotherapeutics, Inc. IOVA incurred a loss of 47 cents per share in second-quarter 2023,...
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study
Zacks via Yahoo Finance· 5 months agoExelixis, Inc. EXEL entered into a clinical collaboration with clinical-stage company Arcus...
Exelixis (EXEL) Announces Results From Phase II HNSCC Study
Zacks via Yahoo Finance· 2 years agoExelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with...
Is Exelixis' (EXEL) Growth Story Likely to Continue?
Zacks via Yahoo Finance· 2 years agoExelixis EXEL, an oncology-focused company, maintains momentum on the back of the solid performance of its lead drug Cabometyx amid stiff competition...